Exxonmobil Investment Management Inc. TX Has $12.11 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Exxonmobil Investment Management Inc. TX reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 63,760 shares of the medical research company’s stock after selling 9,324 shares during the period. Exxonmobil Investment Management Inc. TX’s holdings in Thermo Fisher Scientific were worth $12,107,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bank of Nova Scotia Trust Co. bought a new stake in shares of Thermo Fisher Scientific during the third quarter worth about $106,000. Shine Investment Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $113,000. Chicago Partners Investment Group LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $108,000. Ropes Wealth Advisors LLC increased its position in shares of Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after acquiring an additional 97 shares in the last quarter. Finally, Atlantic Trust LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $138,000. 86.25% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Inc. (NYSE:TMO) traded up $1.51 during midday trading on Tuesday, hitting $210.17. 1,486,400 shares of the stock traded hands, compared to its average volume of 1,542,556. Thermo Fisher Scientific Inc. has a one year low of $140.00 and a one year high of $211.54. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $83,370.00, a price-to-earnings ratio of 35.68, a P/E/G ratio of 1.71 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. During the same quarter in the previous year, the firm posted $2.03 earnings per share. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. equities research analysts expect that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Monday, January 15th. Stockholders of record on Friday, December 15th were given a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend was Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.19%.

Several research firms have recently commented on TMO. Jefferies Group reissued a “hold” rating and set a $195.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Leerink Swann restated an “outperform” rating and set a $200.00 price target (down from $216.00) on shares of Thermo Fisher Scientific in a report on Monday, December 4th. BTIG Research started coverage on shares of Thermo Fisher Scientific in a report on Friday, January 5th. They set a “buy” rating and a $230.00 price target on the stock. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Goldman Sachs Group started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, September 26th. They issued a “buy” rating and a $225.00 target price on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have assigned a buy rating to the company. Thermo Fisher Scientific presently has a consensus rating of “Buy” and an average target price of $212.21.

In other news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $191.74, for a total value of $9,587,000.00. Following the sale, the chief executive officer now owns 302,577 shares of the company’s stock, valued at $58,016,113.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.49% of the company’s stock.

WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/16/thermo-fisher-scientific-inc-tmo-shares-sold-by-exxonmobil-investment-management-inc-tx.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply